FOLH1 and metastatic neoplasm: The main clinical utility of PSMA PET in men with biochemical recurrence is to stratify patients who have local recurrence or limited metastatic disease that may be amenable to focal ablative therapies from those who have more extensive metastatic disease and would benefit from systemic therapy.